Price (delayed)
$39
Market cap
$3.19B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2
Enterprise value
$3.08B
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved,
There are no recent dividends present for VRNA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.